

Press Release

Granules India's FY14 Sales increase 43% to Rs. 1,096 Cr.; Net Profit jumps 131% to Rs. 75 Cr

Hyderabad, April 24, 2014: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced financial results for its fiscal year ended March 31, 2014. Granules consolidated net sales increased 43% to Rs. 1,096 Cr. while consolidated net profit increased 131% to Rs. 75 Cr.

Financial Highlights for Fiscal Year ended March 31, 2014

- Net Sales: Rs. 1,096 Cr., an increase of 43% compared to Rs. 764 Cr. in FY13
- EBITDA: Rs. 163 Cr., an increase of 87% compared to Rs. 87 Cr. in FY13
- PBT: Rs. 112 Cr., an increase of 143% compared to Rs. 46 Cr. in FY13
- Net Profit: Rs. 75 Cr., an increase of 131% compared to Rs. 33 Cr. in FY13
- Basic EPS: Rs. 37.20 per share as compared to Rs. 16.21 per share in FY13.

The Company reported record sales of Rs. 1,096 Cr. including Rs. 317 Cr. in Q4FY14, its highest revenue in a quarter. The Q4FY14 revenue was 55% higher than the corresponding quarter in FY13 and marks the sixth consecutive quarter of higher sequential sales.

Growth was driven by strong performance across all manufacturing facilities including the Company's Chinese JV. The primary growth driver in FY14 was led by the Company's commercialization of its PFI and Finished Dosage expansion at the Gagillapur facility. The Company improved utilization in the newly expanded facility throughout the year and expects to continue improving utilization in the future. In addition, the API facilities continued to increase production which contributed to strong sales.

On a standalone basis, the Finished Dosage business contributed the largest share of revenue at 35% while PFI and API contributed 33% and 32%, respectively. This is compared to 31%, 32% and 37% for Finished Dosages, PFI and API, respectively in FY13.

In addition to strong revenue growth, profitability margins expanded in the fiscal year. EBITDA grew 87% to Rs. 163 Cr. in FY14; the margin expanded 345 basis points to 14.8% During Q4FY14, the EBITDA margin was 16.2%, the highest for the year and an improvement of 227 basis points as compared to the corresponding quarter in FY13. Net Profit was Rs. 75 Cr., the highest in the Company's history and an increase of 131% as compared to FY13. The net profit margin improved by 261 basis points to 6.9%

Profitability outpaced revenue growth due to several reasons. First, the Company improved its economy of scale by increasing production utilization in its newly expanded PFI and Finished Dosage capacity at the Gagillapur facility. Due to the increased utilization, the product mix shifted more towards finished dosages which bolstered profitability. Also, due to the Company's focus on operational excellence, the API units also increased capacity through de-bottlenecking which drove profitability. Granules believes the profitability margins from the standalone operations are sustainable.

Due to the Company's strong performance, the Board of Directors has recommended to increase the dividend to 35% of equity value or Rs. 3.50/share from the rate of 20% (Rs.2.00 per share) that was paid in fiscal year 2013.



"The past fiscal year was exciting for Granules. We were able to increase sales while improving profitability due to our relentless focus on delivering high-quality material at a cost-effective price. We believe our product portfolio offers compelling opportunities and we will continue to strengthen our leadership position. In addition to growing our core business, we have been looking at opportunities to diversify our sales by leveraging our core competency of efficient manufacturing. In FY14, Granules made its first acquisition by purchasing Auctus Pharma. The acquisition of Auctus fits into our strategy of being a fully integrated manufacturer while diversifying our product portfolio by adding high-value products with significant market demand. In the short-to-midterm, we will focus on selling APIs from the Auctus portfolio to customers in the regulated markets. Over the long-term, we will add value by offering finished dosages from select APIs in the same portfolio. While we're certainly happy with the progress we made in FY14, we have our eyes toward the future. We will continue to strengthen our model and build systems that are sustainable as we continue to scale-up" said Krishna Prasad, Managing Director of Granules India.

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:

Gayatri Ganesh Genesis Burson-Marsteller +91 9703700884 gayatri.ganesh@bm.com

Appendix



PAR						(D = !- - - -)
	TI					(Rs in Lakhs)
	Statement of Consolidated	Audited Results f		Corresponding 3	Year to date	
SI No.	Particulars	3 Months ended 31 March, 2014	Preceding 3 Months ended 31 Dec, 2013	Months ended 31 March, 2013 in the previous	figures for current year ended 31	Previous year ended 31 March, 2013
		Audited	Unaudited	year Audited	March, 2014 Audited	Audited
1	Income from Operations (a) Net sales / Income from Operations (Net of Excise duty)					
	(b) Other operating income	31,747.31	28,405.11	20,438.33	109,586.48	76,437.3
2	Total Income from operations (net) Expenses	31,747.31	28,405.11	20,438.33	109,586.48	76,437.
	(a) Cost of material Consumed (b) Purchases of stock-in-trade	18,889.90	16,939.69	11,860.87	67,643.92	47,768.9
	(c) Changes in Inventories of Finished goods,Work in progress and Stock-in-trade	331.12	(964.20)	(209.19)	(3,118.80)	(1,077.0
	(d) Employee Benefits Expense	2,354.32	2,241.40	1,543.16	8,788.56	5,971.1
	e) Depreciation f) Manufacturing Expenses	1,056.37 1,759.68	741.44 1,930.64	617.23 1,545.23	2,981.25 6,702.12	2,308.4 5,752.3
	g) Freight outward & clearing charges h) R & D Expenses	1,628.66 300.88	1,238.12 122.17	1,339.70 109.92	5,274.38 679.22	4,374.4 546.0
	i) Other expenditure Total	1,474.86 27,795.80	2,390.59 24,639.85	1,495.05 18,301.96	7,788.03 96,738.68	4,599.3 70,243. 7
3	Profit from Operations before Other Income, finance costs & Exceptional Items (1- 2)	3,951.50	3,765.26	2,136.38	12,847.79	6,193.5
4	Other Income	148.87	3,703.20 47.78	101.20	431.09	206.0
5	Profit from Ordinary activities before finance costs and exceptional items (3 - 4)	4,100.37	3,813.04	2,237.58	13,278.89	6,399.
7	Finance Costs Profit from Ordinary activities after finance costs but	778.90 3,321.47	455.26 3,357.78	427.75 1,809.83	2,042.73 11,236.16	1,767.1 4,632. 4
8	before exceptional items (5 - 6) Exceptional items	-	-	-	-	
9	Profit from Ordinary activities before Tax (7 - 8) Tax expense	3,321.47 958.97	3,357.78 1,177.25	1,809.83 568.56	11,236.16 3,713.03	4,632.4
11	Net Profit from ordinary activities after tax (9 - 10)	2,362.50	2,180.53	1,241.27	7,523.13	1,375.7 3,256. 7
12 13	Extraordinary items (net of tax expense) Net Profit for the period (11 - 12)	2,362.50	2,180.53	1,241.27	7,523.13	3,256.7
14	Paid-up share capital	2,028.12	2,028.12	2,012.62	2,028.12	2,012.6
	(Face Value of Rs.10/- each) Reserves excluding Revaluation Reserve					
15 16	Earnings per Share	33,542.61	30,717.75	25,441.02	33,542.61	25,441.0
	(a) Basic Earnings per share (Rs.)* (b) Diluted Earning per share (Rs) *	11.68 11.46	10.80 10.60	6.18 6.02	37.20 36.49	16.2 15.7
PAR	T II					
	Select Information f	or the Quarter an	Preceding 3	Corresponding 3		
SI No.	Particulars	3 Months ended 31 March, 2014	Months ended	Months ended 31 March, 2013	Current year ended	Previous year ended
NO.		31 March, 2014	2013	in the previous year	31 March, 2014	31 March, 2013
. 1	Dublic Shareholding			7		
1	Public Shareholding - No. of shares	10,370,988	10,371,180	11,182,097	10,370,988	11,182,09
2	- Percentage of shareholding Promoters and promoter group	51.14%	51.14%	55.56%	51.14%	55.56
	Shareholding					
	a) Pledged/Encumbered Number of shares	2,445,830	2,445,830	840,000	2,445,830	840,00
	Percentage of shares to promoter group Percentage of shares to total capital	24.68% 12.06%	24.68% 12.06%	9.36% 4.17%	24.68% 12.06%	9.36 ⁴
	b) Non-encumbered	12.0070				
			7,464,144	8,104,057	7,464,336	8,104,05
	Number of shares Percentage of shares to promoter group	7,464,336 75.32%	75.32%	90.61%	75.32%	90.61%
	Number of shares	75.32% 36.80%		90.61% 40.27%	75.32% 36.80%	
No.	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars	75.32%	75.32%			
No.	Number of shares Percentage of shares to promoter group Percentage of shares to total capital	75.32% 36.80% 3 Months ended	75.32%			
No.	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter	75.32% 36.80% 3 Months ended 31 March, 2014	75.32%			
No.	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS	75.32% 36.80% 3 Months ended 31 March, 2014	75.32%			
No.	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20	75.32%			
No. 3	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL	75.32% 36.80%	40.27%	36.80%	
No. B	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter ef financial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review	75.32% 36.80%	40.27%	36.80%	
) The and	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter e financial results for the quarter and year ended 31st March, a provided by the Board of Directors at its meeting held on 24 e auditors of the company have audited the above financial results for the company have audited the above financial results for the company have audited the above financial results for the consolidated financial statem	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. suits.	75.32% 36.80% wed by the Audit Cc	40.27% mmittee on 23rd April s USA Inc, Granules	36.80%	40.27
) The and () The (i) The	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter infinitely a subject of the promote of the pro	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. suits.	75.32% 36.80% wed by the Audit Cc	40.27% mmittee on 23rd April s USA Inc, Granules	36.80%	40.27
) The and 3) The 3) The GI Gr	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter In innancial results for the quarter and year ended 31st March, at approved by the Board of Directors at its meeting held on 24 e auditors of the company have audited the above financial rese subsidiaries considered for the consolidated financial statem Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owne anules Omnichem Pvt Ltd (50% Joint Venture Companies). Ing the year ended March 31, 2014 Granules Singapore Pte.	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. sults. ent as on 31st March d subsidiary compan	75.32% 36.80% wed by the Audit Co , 2014 are Granules es) and Granules E	mmittee on 23rd Apri s USA Inc, Granules s locause Pharmaceu	36.80% I, 2014 Singapore Pte. Ltd. tical Co., Ltd.,	40.27
No. 3 The ance and Griff Griff Du www.	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter e financial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 e auditors of the company have audited the above financial results for the consolidated financial staten L Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. ring the quarter, the Company acquired Auctus Pharma Limited, 14 th February, 2014. The accounts of Auctus Pharma Limited.	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. sults. sults. sults. de subsidiary companied to a consideration mitted were consolidate.	75.32% 36.80% 36.80% wed by the Audit Co., 2014 are Granules les) and Granules Eliquidated. of Rs. 120 crores, ved with the Compa	mmittee on 23rd Apri s USA Inc, Granules : locause Pharmaceu	I, 2014 Singapore Pte. Ltd. lcal Co., Ltd. owned subsidiary mencing	40.27
No. 3 The ance Gli Gr. Gr. Gr. Du w	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 a purious of the company have audited the above financial researched in the consolidated financial staten to Life Sciences Pvt Ltd. Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies). Tings the quarter, the Company acquired Auctus Pharma Limite. 1.6.1 14 th February, 2014. The accounts of Auctus Pharma Limit (1.6.5 the Auctus Pharma Limit (1.6.5 the Auctus Pharma Limit (1.6.5 the Auctus Pharma Limite (1	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. sults. sults. sent as on 31st March de subsidiary companict.d. (Singapore) was sed for a consideration milted were consolider	75.32%, 36.80% 36.80% wed by the Audit Co., 2014 are Granules E liquidated, of Rs.120 crores, v ed with the Compa	mmittee on 23rd Apri s USA Inc, Granules s liocause Pharmaceu which became wholly ny for the period com	36.80% I, 2014 Singapore Pte. Ltd. icial Co., Ltd., owned subsidiary mencing arr figures.	40.27
No. 3 The annual of the state	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 a purpoved by the Board of Directors at its meeting held on 24 e auditors of the company have audited the above financial rese subsidiaries considered for the consolidated financial staten Life Sciences Pvt Ltd. Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Ptering the quarter, the Company acquired Auctus Pharma Limit (v.e.f 14 th February, 2014. The accounts of Auctus Pharma Limit (v.e.f 14 th February, 2014. Therefore, current quarter and year is company has applied to the Bombay Stock Exchange, the Evitin Granules India Limited with effect from 1st April 2013, the	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 20 NIL 2014 have been review th April, 2014. sults. sults. sults. disubsidiary compani Ltd. (Singapore) was lad for a consideration mitted were consolidat ligures are not compa essignated Stock Exa	wed by the Audit Co. , 2014 are Granules E iquidated. of Rs.120 crores, v ed with the Compa rable with the corre nance for approval, v	mmittee on 23rd Apri s USA Inc, Granules s siccause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A uctus Pharma Limit	J6.80% I, 2014 Singapore Pte. Ltd. tical Co., Ltd., owned subsidiary mencing ar figures. Lctus Pharma Lim dwill make an ap dwill make an ap	40.27
No.) The ance and the state of the state o	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter e financial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 a auditors of the company have audited the above financial rese subsidiaries considered for the consolidated financial stater L Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte, ring the quarter, the Company acquired Auctus Pharma Limited (v.e.f 14 th February, 2014. The accounts of Auctus Pharma Limited on 14th February, 2014. The accounts of Auctus Pharma Limited et company has applied to the Bombay Stock Exchange, the De	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. suits. Ltd. (Singapore) was is defor a consideration mitted were consolidat figures are not compa escinated Stock Excl. Appointed Date. On r	wed by the Audit Co. , 2014 are Granules Eliquidated. of Rs.120 crores, ved with the Comparable with Carolles India	mmittee on 23rd Apri s USA Inc, Granules s locause Pharmaceu vhich became wholly ny for the period com sponding previous ye of amalgamation of A Auctus Pharma Limit Limited. Subsequent	J6.80% I, 2014 Singapore Pte. Ltd. tical Co., Ltd., owned subsidiary mencing ar figures. Lctus Pharma Lim dwill make an ap dwill make an ap	40.27
No.) The ance and the street and t	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter In improved by the Board of Directors at its meeting held on 24 a auditors of the company have audited the above financial rese subsidiaries considered for the consolidated financial stater Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. Iring the quarter, the Company acquired Auctus Pharma Limit v.e.f 14 th February, 2014. The accounts of Auctus Pharma Limit v.e.f 14 th February, 2014. The accounts of Auctus Pharma Limit v.e.f 14 th February, 2014. The accounts of Auctus Pharma Limit v.e.f 14 th February, 2014. The affore, current quarter and year is company has applied to the Bombay Stock Exchange, the Chrible High Court of Andhra Pradesh, the accounts of Granul sound to the Notification No.G.S.R.e.13(E), dt.29.12.2011 issu	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. sults. utts. disubsidiary compan Ltd. (Singapore) was lad for a consideration mitted were consolidat figures are not compa	wed by the Audit Co , 2014 are Granules es) and Granules E iquidated. of Rs.120 crores, v ed with the Compa rable with the corre ange for approval of the correlation	mmittee on 23rd Apri s USA Inc, Granules s siocause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A uctus Pharma Limited. Subsequent liv.	I, 2014 Singapore Pte. Ltdical Co., Ltd. owned subsidiary mencing par figures. uctus Pharma Lim d will make an ap to approval of	40.27
No. 3 The anomalous for the state of the s	Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Received during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 a purious of the company have audited the above financial rese subsidiaries considered for the consolidated financial staten Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies). ring the year ended March 31, 2014 Granules Singapore Pte. ring the quarter, the Company acquired Auctus Pharma Limite (vs.6.1 t4 th February, 2014. The accounts of Auctus Pharma Limite (vs.6.1 t4 th February, 2014. Therefore, current quarter and year ecompany has applied to the Bombay Stock Exchange, the Diff Granula Holl of the Court of Andhra Pradesh for amalgamation of Auchor'ble High Court of Andhra Pradesh he accounts of Granul results to the Notification No.G.S.R.913(E), dt.29.12.2011 issuins and losses on lonans utilised for purchase of fixed assets.	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. suits. lent as on 31st March ds subsidiary compani Ltd. (Singapore) was lad for a consideration mitted were consolitgures are not compa residented Stock Excl. Appointed Date. On rotus Pharma Limited es India Limited will b ed by the Ministry of C stakes for the Quarter of the Courter of the	wed by the Audit Co , 2014 are Granuler es) and Granules E iquidated. of Rs.120 crores, v ed with the Compa rable with the corre lange for approval a with Granules India e revised according ompany Affairs, the r ended 31 March 2	mmittee on 23rd Apri s USA Inc, Granules s slocause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A uctus Pharma Limit Limited. Subsequent liv. c company has opted	I, 2014 Ii, 2014 Singapore Pte. Ltd. tical Co., Ltd., owned subsidiary menga fra figures. Luctus Pharma Lim at to approval of to capitalise foreid to fixed assets.	40.27
No.) The anomal and anomal an	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter a proved by the Board of Directors at its meeting held on 24 e auditors of the company have audited the above financial rese subsidiaries considered for the consolidated financial state. Life Sciences Pvt Ltd. Auctus Pharma Limited (Wholly owne anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. ring the quarter, the Company acquired Auctus Pharma Limited (Value) and the february, 2014. The accounts of Auctus Pharma Limom 14th February, 2014. The accounts of Auctus Pharma Limited (Value) are occompany has applied to the Bombay Stock Exchance, the Divith Granules India Limited with effect from 1st April 2013, the Horn'ble High Court of Andria Pradesh for amalgamation of Auchor'ble High Court of Andria Pradesh, the accounts of Granul sus and losses on loans utilised for purchase of fixed assets.	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review the April, 2014. sults. sults. do a consideration mited were consolidat ligures are not companited with a consideration to the April and t	wed by the Audit Co. , 2014 are Granules ies) and Granules E liquidated, of Rs.120 crores, v ed with the Compa rable with the corre anage for approval, with Granules India e revised according company Affairs, the company Affairs, the r ended 31 March 2 f 644.20 Lakhs) w.	mmittee on 23rd Apri s USA Inc, Granules : locause Pharmaceu vhich became wholly ny for the period com sponding previous ye of amalcamation of A uctus Pharma Limite Limited. Subsequent ly. c company has opted 013) was transferred as transferred to fixed	I, 2014 Singapore Pte. Ltd. dical Co., Ltd. owned subsidiary mencing ara figures. uctus Pharma Lim ad will make an ap to approval of to capitalise foreid to capitalise foreid assets.	40.27
No.) Thomano and another the state of the	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter In improved by the Board of Directors at its meeting held on 24 a purpoved by the Board of Directors at its meeting held on 24 a puditors of the company have audited the above financial rese usubsidiaries considered for the consolidated financial stater Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly own anules Omnichem Pvt Ltd (60% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. Ing the quarter, the Company acquired Auctus Pharma Limit reaf 14 th February, 2014. The accounts of Auctus Pharma Limit on 14th February, 2014. The force, current quarter and year is company has applied to the Bombay Stock Exchange, the Dwith Granules India Limited with effect from 1st April 2013, the 1-on'ble High Court of Andhra Pradesh, the accounts of Granul susuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issu ins and losses on loans utilised for purchase of fixed assets. During the quarter Gain of Rs.429.94 lakhs (Gain of Rs.104.55 buring the financial year 2013-14 loss of Rs.1,562.85 (Previou per clause 41 of the listing agreement, the Company has opte	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been reviet th April, 2014. suits. uts. can a son 31st March d subsidiary compan Ltd. (Singapore) was is defor a consideration mited were consolidat figures are not compa esignated Stock Excl Appointed Date. On r tus Pharma Limited ses India Limited will be d by the Ministry of C stakes for the Quarte is vear 2012-13 losses d to publish only come in the stock exchanges the stock of the country of the count	wed by the Audit Co. , 2014 are Granules es) and Granules E iquidated. of Rs.120 crores, v ed with the Compa rable with the corre ange for approval, v with Granules India cerejt of approval, v or ervised according company Affairs, the r ended 31 March 2 f 644.20 Lakhs) w olidated financial r ostidated financial r	mmittee on 23rd Apri s USA Inc, Granules : Siccause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A uctus Pharma Limited. Subsequent liv. a company has opted 013) was transferred so transferred to fixee suits. The stand-alo soults.	I, 2014 Singapore Pte. Ltd. dical Co., Ltd. owned subsidiary mencing ara figures. uctus Pharma Lim ad will make an ap to approval of to capitalise foreid to capitalise foreid assets.	40.27
No. 3) The annex of the state of the stat	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter In approved by the Board of Directors at its meeting held on 24 a purtory of the company have audited the above financial researched to the company have audited the above financial researched to the company have audited the above financial researched to the company and the singapore Pte. Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owner anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. Ing the quarter, the Company acquired Auctus Pharma Limite. et. 14 th February, 2014. The accounts of Auctus Pharma Limite. et. 14 th February, 2014. The accounts of Auctus Pharma Limite of the High Court of Andhra Pradesh, the accounts of Granul with Granules India Limited with effect from 1st April 2013, the don'ble High Court of Andhra Pradesh, the accounts of Granul svant to the Notification No.G.S.R.913(E), dt.29.12.2011 issuins and losses on loans utilised for purchase of fixed assets. During the quarter Gain of Rs.429.94 laths (Gain of Rs.104.55) During the financial year 2013-14 loss of Rs.1,562.85 (Previour procession of the procession of the Company has opted a available for persual on the Company's website as well as o wow.granulesindia.com, www.bseindia.com and www.nse-india Company operates only in the segment of Pharmaceuticals.	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 20 NIL 2014 have been review the April, 2014. sults. usults. disubsidiary companitude of a consideration mitted were consolidat figures are not companited were consolidat figures are not companited were consolidated in the April (Singapore) was led for a consideration consolidated figures are not companited were consolidated figures are not companited were consolidated figures are not companited were solved to be solved to the Appointed Date. On notus Pharma Limited will be do by the Ministry of C is Lakhs for the Quarted via Superior 2012-31 aloss coded to publish only consolved in the stock exchanges accommended.	wed by the Audit Co. , 2014 are Granules es) and Granules E iquidated. of Rs.120 crores, v ed with the Compa rable with the corre ange for approval, v with Granules India cerejt of approval, v or ervised according company Affairs, the r ended 31 March 2 f 644.20 Lakhs) w olidated financial r ostidated financial r	mmittee on 23rd Apri s USA Inc, Granules : Siccause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A uctus Pharma Limited. Subsequent liv. a company has opted 013) was transferred so transferred to fixee suits. The stand-alo soults.	I, 2014 Singapore Pte. Ltd. dical Co., Ltd. owned subsidiary mencing ara figures. uctus Pharma Lim ad will make an ap to approval of to capitalise foreid to capitalise foreid assets.	40.27
No. State	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter a approved by the Board of Directors at its meeting held on 24 a purious of the company have audited the above financial research as a unditors of the company have audited the above financial research as a subsidiaries considered for the consolidated financial stater Life Sciences Pvt Ltd. Auctus Pharma Limited (Wholly owner anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. Ing the quarter, the Company acquired Auctus Pharma Limite (vel. 14 th February, 2014. The accounts of Auctus Pharma Limite (vel. 14 th February, 2014. The refore, current quarter and year is company has applied to the Bombay Stock Exchange, the Devith Granules India Limited with effect from 1st April 2013, the Horible High Court of Andhra Pradesh, the accounts of Granul suant to the Notification No.G.S.R.913(E), dt.29.12.2011 issue ins and losses on loans utilised for purchase of fixed assets. During the quarter Gain of Rs.429.94 lakish (Gain of Rs.104.55) During the quarter Gain of Rs.429.94 lakish (Gain of Rs.104.55) During the financial year 2013-14 loss of Rs.1,562.85 (Previous per clause 41 of the listing agreement, the Company has opte a available for persual on the Company's website as well as o we cannot be company operates only in the segment of Pharmace-licids gures are regrouped wherever necessary.	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review the April, 2014. Suits. 2015 have been review the April, 2014. Suits. 2016 have been review the April, 2014. Suits. 2017 have been review the April, 2014. Suits. 2017 have been review the April, 2014. Suits and Suits. Suits and	wed by the Audit Co. , 2014 are Granules E. iquidated. of Rs.120 crores, v. ed with the Comparable with the corre range for approval of the corresion of the	mmittee on 23rd Apri s USA Inc, Granules : Siocause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A uctus Pharma Limit Limited. Subsequent ly. c company has opted o13) was transferred s transferred to fixe ssults. The stand-alo d below:	I, 2014 Singapore Pte. Ltd. dical Co., Ltd. owned subsidiary mencing ara figures. uctus Pharma Lim ad will make an ap to approval of to capitalise foreid to capitalise foreid assets.	40.27
No. 3) The ance are a constant of the state of the sta	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Received during the quarter Remaining unresolved at the end of the duarter Remaining unresolved at the end of the duarter is financial results for the quarter and year ended 31st March, a darproved by the Board of Directors at its meeting held on 24 is auditors of the company have audited the above financial rese subsidiaries considered for the consolidated financial statem Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. ring the quarter, the Company acquired Auctus Pharma Limiter Life 14th February, 2014. The refore, current quarter and year e company has applied to the Bombay Stock Exchange, the Le with Granules India Limited with effect from 1st April 2013, the don'ble High Court of Andhra Pradesh for amalgamation of Au- chorble High Court of Andhra Pradesh he accounts of Granul resuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issue is and losses on loans utilised for purchase of fixed assets. During the quarter Gain of Rs.429.94 lakhs (Gain of Rs.104.55 Unring the financial year 2013-14 loss of Rs.1,562.85 (Previou per clause 41 of the listing agreement, the Company has opto a available for persual on the Company's website as well as o www.ramulesindia.com, www.bseindia.com and www.nse-indie of Company operates only in the segment of Pharmaceuticals. year of the propulse o	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review the April, 2014. sults. untern as on 31st March do subsidiary companied for a consideration mitted were consolidat figures are not companied with the April, 2014. Substantial Companied Companied Pate On the Month of the Mon	wed by the Audit Co. , 2014 are Granules ies) and Granules E liquidated. of Rs.120 crores, v ed with the Compa rable with the corre ange for approval, o eceipt of approval, with Granules India e revised according company Affairs, the r ended 31 March 2 f 644.20 Lakhs) w solidated financial re s' websites as state each. Employee Stock O Employee Stock O	mmittee on 23rd Apri s USA Inc, Granules s slocause Pharmaceu which became wholly ny for the period com sponding previous y of amalgamation of A vuctus Pharma Limit Limited. Subsequent iv. e company has opted or 13) was transferred st transferred to fixee sutts. The stand-alo d below:	I, 2014 Singapore Pte. Ltd. tical Co., Ltd., owned subsidiary mencing par figures. uctus Pharma Lim ad will make an ap to approval of to capitalise forei to fixed assets. assets. ne financial result	litted plication to gn currency
No. B III) The annual	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Beceived during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Be financial results for the quarter and year ended 31st March, a gaproved by the Board of Directors at its meeting held on 24 e auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited whollow of the company acquired Auctus Pharma Limited. If the February, 2014. The accounts of Auctus Pharma Limited of the quarter and year in company has applied to the Bombay Stock Exchange, the Dwith Granules India Limited with effect from 1st April 2013, the don'ble High Court of Andrhar Pradesh for amalgamation of Auditor Pradesh for amalgamation of Aud	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review the April, 2014. sults. untern as on 31st March do subsidiary companied for a consideration mitted were consolidat figures are not companied with the April, 2014. Substance of Research and 2	wed by the Audit Co. , 2014 are Granules ies) and Granules E liquidated. of Rs.120 crores, v ed with the Compa rable with the corre ange for approval, o eceipt of approval, with Granules India e revised according company Affairs, the r ended 31 March 2 f 644.20 Lakhs) w solidated financial re s' websites as state each. Employee Stock O Employee Stock O	mmittee on 23rd Apri s USA Inc, Granules s slocause Pharmaceu which became wholly ny for the period com sponding previous y of amalgamation of A vuctus Pharma Limit Limited. Subsequent iv. e company has opted or 13) was transferred st transferred to fixee sutts. The stand-alo d below:	I, 2014 Singapore Pte. Ltd. tical Co., Ltd., owned subsidiary mencing par figures. uctus Pharma Lim ad will make an ap to approval of to capitalise forei to fixed assets. assets. ne financial result	litted plication to gn currency
No. B III) The annual	Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Received during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter In approved by the Board of Directors at its meeting held on 24 a auditors of the company have audited the above financial rese subsidiaries considered for the consolidated financial staten Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies). Ting the quarter, the Company acquired Auctus Pharma Limite (4.6.1 4th February, 2014. The accounts of Auctus Pharma Limite (4.6.1 4th February, 2014. The accounts of Auctus Pharma Limite (4.6.1 4th February, 2014. Therefore, current quarter and year ecompany has applied to the Bombay Stock Exchange, the Director of Auctus Pharma Limite (4.6.1 4th February, 2014. Therefore, current quarter and year ecompany has applied to the Bombay Stock Exchange, the Director of Auctus Pharma Limite (4.6.1 4th February, 2014. Therefore, current quarter and year ecompany has applied to the Bombay Stock Exchange, the Director of Auctus Pharma Limite (4.6.1 4th February, 2014. Therefore, current quarter and year ecompany has applied to the Bombay Stock Exchange, the Director of Auctus Pharma Limite (4.6.1 4th February, 2014. Therefore) percentage of fixed assets. Percentage of the light Court of Andhra Pradesh for amalgamation of Aucturing the quarter Gain of Rs. 4.29.9 4 tables (Gain of Rs. 1.04.55). During the quarter Gain of Rs. 4.29.9 4 tables (Gain of Rs. 1.04.55). During the financial year 2013-14 loss of Rs. 1.562.85 (Previou per clause 4th of the listing agreement, the Company has opte a available for persual on the Company's website as well as own, granulesindia.com, www.besindia.com and www.nes-indic ecompany operates only in the segment of Phar	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review the April, 2014. suits. Ltd. (Singapore) was ad for a consideration mited were consolidat ligures are not compassionated Stock Excl Appointed Date. On rusus Pharma Limited were consolidated in the April, 2014. Ltd. (Singapore) was ad for a consideration mited were consolidated sigures are not compassionated Stock Excl Appointed Date. On rusus Pharma Limited well be signed as India Limited will be signed by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is a company of the Company's with the Company's a unditted figures for F	wed by the Audit Co. , 2014 are Granules ies) and Granules E liquidated. of Rs.120 crores, v ed with the Compa rable with the corre ange for approval, o eceipt of approval, with Granules India e revised according company Affairs, the r ended 31 March 2 f 644.20 Lakhs) w solidated financial re s' websites as state each. Employee Stock O Employee Stock O	mmittee on 23rd Apri s USA Inc, Granules s slocause Pharmaceu which became wholly ny for the period com sponding previous y of amalgamation of A vuctus Pharma Limit Limited. Subsequent iv. e company has opted or 13) was transferred st transferred to fixee sutts. The stand-alo d below:	I, 2014 I, 2014 Singapore Pte. Ltdicial Co., Ltd., owned subsidiary mencing ar figures. Letus Pharma Lim at the approval of to capitalise foreid to fixed assets. lassets. ne financial results ure up to the 3rd of the control of t	iited plication to gn currency
No. B III) The annual	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Received during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 a put of the company have audited the above financial researched to the company have audited the above financial researched with the consolidated financial staten to 15 center of the company have audited the above financial researched with the consolidated financial staten to 16 center of the company have audited the above financial researched with 50 center of the company acquired Auctus Pharma Limite (Molly) owns anules Omnichem Pvt Ltd (50% Joint Venture Companies). Ting the year ended March 31, 2014 Granules Singapore Ptering the quarter, the Company acquired Auctus Pharma Limite via 16 center of 18 ce	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. suits. lent as on 31st March disubsidiary companion. Ltd. (Singapore) was lad for a consideration mitted were consolidigures are not compa residented Stock Excl. Appointed Date. On roctus Pharma Limited des India Limited will be de by the Ministry of C stakes for the Quarte is year 2012-13 loss c do publish only cons in the stock exchanger a company in the stock exchanger a company is a sudited figures for F. 31-Mar-14	wed by the Audit Co. 2014 are Granules is and Granules E iquidated. of Rs. 120 crores, v ed with the Compa rable with the Compa rable with the corres ange for approval, o except of approval, o except of approval, o f 644. 20 Lakhs) w solidated financial re s' websites as state as websites as state Employee Stock O y 2014 and the pub Quarter ended 31-Dec-13	mmittee on 23rd Apri s USA Inc, Granules : siccause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A Auctus Pharma Limited. Subsequent liv. e company has opted 013) was transferred so transferred to lixee sults. The stand-alo d below: pition Scheme(s). lished year to date fig 31-Mar-13	I, 2014 I, 2014 Singapore Pte. Ltdicial Co., Ltd., owned subsidiary mencing ar figures. Lutus Pharma Lim ad will make an ap to approval of to capitalise forei d to fixed assets. lassets. lassets. ure up to the 3rd of Year 31-Mar-14	40.27' iited plication to gn currency s quarter ended 31-Mar-13
No. 3) The anomal and anomal anoma	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Received during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 a put of the company have audited the above financial researched to the company have audited the above financial researched with the consolidated financial staten to 15 center of the company have audited the above financial researched with the consolidated financial staten to 16 center of the company have audited the above financial researched with 50 center of the company acquired Auctus Pharma Limite (Molly) owns anules Omnichem Pvt Ltd (50% Joint Venture Companies). Ting the year ended March 31, 2014 Granules Singapore Ptering the quarter, the Company acquired Auctus Pharma Limite via 16 center of 18 ce	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review the April, 2014. suits. Ltd. (Singapore) was ad for a consideration mited were consolidat ligures are not compassionated Stock Excl Appointed Date. On rusus Pharma Limited were consolidated in the April, 2014. Ltd. (Singapore) was ad for a consideration mited were consolidated sigures are not compassionated Stock Excl Appointed Date. On rusus Pharma Limited well be signed as India Limited will be signed by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is Lakhs for the Quarte is veez consolidated by the Ministry of C is a company of the Company's with the Company's a unditted figures for F	wed by the Audit Co. , 2014 are Granules E. iquidated. of Rs.120 crores, ved with the Comparable with the Comparable with the corning for approval of the company Affairs, the rended 31 March 2 of 644.20 Lakhs) will olidated financial residence of the company for the company for the company for the company affairs, the rended 31 March 2 of 644.20 Lakhs) will olidated financial residence of the company for the co	mmittee on 23rd Apri s USA Inc, Granules : liocause Pharmaceu vhich became wholly ny for the period com sponding previous ye of amalgamation of A vactus Pharma Limit e. Company has opted 1013) was transferred as transferred to fixee sults. The stand-alo d below: ption Scheme(s). lished year to date fig	I, 2014 Singapore Pte. Ltd. clical Co., Ltd. clical Co., Ltd. clical Co., td. clical Co.,	40.27 dited plication to gn currency s ended 31-Mar-13 (Audited)
No. 3) The anomal and anomal anoma	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter a sproved by the Board of Directors at its meeting held on 24 a purtored of the company have audited the above financial research as a cuditors of the company have audited the above financial research as a company and the summary of the company and the singapore Pte. Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owner and the year ended March 31, 2014 Granules Singapore Pte. Ing the quarter, the Company acquired Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The accounts of Auctus Pharma Limiter, etc. 11 4th February, 2014. The Auctus Pharma Limiter, etc. 21 4th Febr	75.32% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review th April, 2014. suits. 2014 have been review th April, 2014. suits. 2014 have been review th April, 2014. suits. 2015 have been review th April, 2014. suits. 2014 have been review th April, 2014. suits. 2015 have been review th April, 2014. Suits. 2015 have been review the suits. 2015 have been review the suits. 2016 hav	wed by the Audit Co. , 2014 are Granules E. iquidated. of Rs.120 crores, v. ed with the Compa rable with the corre anale for approval of sceipt of of	mmittee on 23rd Apri s USA Inc, Granules : Siocause Pharmaceu vhich became wholly ny for the period com sponding previous ye of amalgamation of A vactus Pharma Limit company has opted 1013) was transferre as transferred to fixee sutts. The stand-alo d below: piton Scheme(s). lished year to date fig 31-Mar-13 (Audited)	I, 2014 I, 2014 Singapore Pte. Ltd icial Co., Ltd., owned subsidiary mencing har figures. Little and will make an ap to approval of to capitalise foreit to fixed assets. In assets. In a financial result in a financial	40.27 dited plication to gn currency s ended 31-Mar-13 (Audited) 67,979.1
No. 3) The anomal and anomal anoma	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Received during the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, a approved by the Board of Directors at its meeting held on 24 a put of the company have audited the above financial rese subsidiaries considered for the consolidated financial staten Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owns anules Omnichem Pvt Ltd (50% Joint Venture Companies). ring the year ended March 31, 2014 Granules Singapore Pte. ring the quarter, the Company acquired Auctus Pharma Limite (value). The recompany acquired Auctus Pharma Limite (value) and the state of the state	75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL 2014 have been review to the April, 2014. Suits. 2014 have been review to the April, 2014. Suits. 2014 have been review to the April, 2014. Suits. Suits. 2014 have been review to the April, 2014. Suits. Suits. 2014 have been review to the April, 2014. Suits.	wed by the Audit Co a, 2014 are Granules E iquidated. of Rs.120 crores, v ed with the Compa rable with the corre hange for approval o eccept of approval o eccept o ecce	mmittee on 23rd Apri s USA Inc, Granules : Siocause Pharmaceu which became wholly ny for the period come sponding previous ye of amalgamation of A uctus Pharma Limite Limited. Subsequent liv. e company has opted 1013) was transferred to fixee souths. The stand-alo d below: ption Scheme(s). lished year to date fig 31-Mar-13 (Audited) 17,895.04 1,668.32	I, 2014 I, 2014 Singapore Pte. Ltd. tical Co., Ltd., owned subsidiary memory and the subsidiary memory and the subsidiary memory and to approval of to capitalise foreign to the capitalise foreign to the subsidiary memory and	40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27 40.27
1) The ance ance ance ance ance ance ance anc	Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter at approved by the Board of Directors at its meeting held on 24 a purpoved by the Board of Directors at its meeting held on 24 a cauditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited the above financial rese auditors of the company have audited Auctus Pharma Limited (Wholly owne anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the year ended March 31, 2014 Granules Singapore Pte. Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owne anules Omnichem Pvt Ltd (50% Joint Venture Companies), ring the quarter, the Company acquired Auctus Pharma Limited (Wholly owne anules Omnichem Pvt Ltd (50% Joint Venture Companies). In the year ended March 31, 2014 Granules Singapore Pte. 10 and 14th February, 2014. The accounts of Auctus Pharma Limited (Wholly owne anules Omnichem Pvt Ltd (50% Joint Venture Company have an expensive the Company acquired Wholly owne and the theology of the Company and the Pvt Ltd (50% Joint Venture 10 and 14th Ebruary, 2014. Therefore, current quarter and year in the Notification No.G.S.R.913(E), dt.29.12,2011 issue ins and losses on loans utilised for purchase of fixed assets. During the quarter Gain of Rs.429.94 lakins (Gain of Rs.104.55). During the financial year 2013-14 loss of Rs.1,562.85 (Previou per clause 41 of the listing agreement, the Company has opte a available for persual on the Company's website as well as own, granulesindia.com, www.bseindia.com and www.nse-india com own, granulesindia.com, www.bseindia.com and www.nse-india com own, granulesindia.c	75.32% 38 Months ended 31 March, 2014 NIL 20 20 20 NIL 2014 have been review the April, 2014. suits. 2014 have been review the April, 2014. suits. 2014 have been review the April, 2014. suits. 2015 have been review the April, 2014. suits. 2016 have been review the April, 2014. suits. 2017 have been review the April, 2014. suits. 2018 have been review the April, 2014. suits. 2018 have been review the April, 2014. suits. 2018 have been review the April, 2014. Suits defor a consideration mitted were consolidated figures are not compares the Appointed Date. On review the Appointed Date. Suits have been rev	wed by the Audit Co , 2014 are Granules es) and Granules E iquidated. of Rs.120 crores, v ed with the Compa rable with the corre range for approval of sceipt of approval of sce	mmittee on 23rd Apri s USA Inc, Granules s slocause Pharmaceu which became wholly ny for the period com sponding previous ye of amalgamation of A uctus Pharma Limit Limited. Subsequent livia. Subsequent livia. Subsequent of any and a subsequent of a subs	I, 2014 I, 2014 Singapore Pte. Ltd. tical Co., Ltd., owned subsidiary memory and the subsidiary memory and the subsidiary memory and to approval of to capitalise foreign to the capitalise foreign to the subsidiary memory and	plication to gn currency s quarter ended 31-Mar-13



	Consolidated Statement of As	ssets and Liabilities	
		_	(Rs in Lakhs)
		As at	As at
		current year	previous year
	Particulars	end	end
		31 March, 2014	31 March, 2013
Α	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	2,028.12	2,012.62
	(b) Reserves & Surplus	33,542.61	25,441.02
	Sub-total - Shareholders' funds	35,570.73	27,453.65
2	Share Application Money Pending Allotment	25.48	31.50
3	Non-current liabilites		
	(a) Long-term borrowings	30,924.36	17,549.56
	(b) Deferred tax liabilites (Net)	3,030.38	2,447.18
	(c) Long-term provisions	396.57	203.63
	Sub-total - Non-current liabilities	34,351.31	20,200.37
4	Current liabilities		
	(a) Short-term borrowings	10,090.90	8,545.98
	(b) Trade payables	13,554.45	9,184.13
	(c) Other current liabilities	4,777.99	2,377.24
	(d) Short-term provisions	830.48	470.93
	Sub-total - Current liabilities	29,253.81	20,578.28
	TOTAL - EQUITY AND LIABILITIES	99,201.34	68,263.80
В	ASSETS		
1	Non-current assets		
	(a) Fixed Assets		
	(i) Tangible assets	37,465.09	25,008.39
	(ii) Intangible assets	10,782.09	1,337.66
	(iii) Capital work-in-progess	12,455.83	10,880.26
		60,703.01	37,226.30
	(a) Non-current investments	19.14	19.14
	(b) Long-term loans and advances	433.30	1,641.54
	(c) Other non-current assets	353.74	489.30
	Sub-total - Non - current assets	61,509.19	39,376.27
2			0.4= 65
	(a) Current Investments	- 47.440.04	945.92
	(b) Inventories	17,416.34	13,648.23
	(c) Trade receivables	11,090.83	7,102.11
	(d) Cash and cash equivalents	4,174.71	4,170.56
	(e) Short term loans and advances	1,190.49	389.78
	(f) Other current assets	3,819.78	2,630.93
	Sub-total - Current assets	37,692.15	28,887.53
	TOTAL - ASSETS	99,201.34	68,263.80
		For and on behalf of t	ho Board
		roi and on benail of t	HE DUALU
	e: Hyderabad e : 24th April, 2014	Dr.C.Nageswara Rac Chairman	0
valt	: . 44m Aprii, 2014	Chaillian	



						(Rs in Lakhs)
PART	TI Statement of Standalone Audited	Results for the	e guarter and year	ended 31 March. 20	014	
	Statement of Standardie Audited		- quarter ariu year			
SI No.	Particulars	3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013	Corresponding 3 Months ended 31 March, 2013 in the previous year	Current year ended 31 March, 2014	Previous year ended 31 March, 2013
		Audited	Unaudited	Audited	Audited	Audited
1	Income from Operations (a) Net sales / Income from Operations (Net of Excise duty)	29,184.44	26,212.45	17,895.04	100,167.99	67,979.7
	(b) Other operating income	-	-	-	-	-
	Total Income from operations (net)	29,184.44	26,212.45	17,895.04	100,167.99	67,979.7
2	Expenses (a) Cost of material Consumed	15,348.27	14,792.09	10,646.95	58,735.64	42,525.8
	(b) Purchases of stock-in-trade	10,040.27	14,732.03	10,040.93	-	42,020.0
	(c) Changes in Inventories of Finished goods, Work in progress	4 000 00	(70.55)	(500.45)	(007.00)	(7100
	and Stock-in-trade (d) Employee Benefits Expense	1,826.33 1,833.90	(79.55) 1,724.04	(539.17) 1,215.49	(237.62) 6,927.38	(740.6 5,042.0
	e) Depreciation	932.12	666.23	551.60	2,639.79	2,020.
	f) Manufacturing Expenses g) Freight outward & clearing charges	1,370.15 1,608.48	1,618.47 1,225.89	1,254.15 1,328.99	5,518.25 5,184.14	4,431.3 4,304.0
	h) R & D Expenses	274.64	87.38	83.17	567.64	453.0
	i) Other expenditure Total	1,528.86 24,722.76	2,343.71 22,378.25	1,390.36 15,931.53	7,171.74 86,506.96	4,058. 62,094.
	Profit from Operations before Other Income, finance costs &					
	Exceptional Items (1- 2) Other Income	4,461.68 121.98	3,834.20 31.25	1,963.51 101.69	13,661.03 364.75	5,884.8 171.8
	Profit from Ordinary activities before finance costs and exceptional items (3 - 4)	4,583.66	3,865.45	2,065.20	14,025.78	6,056.0
6	Finance Costs	706.91	430.39	396.88	1,892.70	1,649.4
	Profit from Ordinary activities after finance costs but before exceptional items (5 - 6)	3,876.75	3,435.06	1,668.32	12,133.08	4,407.
	Exceptional items Profit from Ordinary activities before Tax (7 - 8)	2 076 75	3,435.06	1 660 22	- 12 122 09	4,407.
	Tax expense	3,876.75 1,272.50	1,135.73	1,668.32 559.01	12,133.08 4,031.94	1,389.0
	Net Profit from ordinary activities after tax (9 - 10)	2,604.26	2,299.33	1,109.31	8,101.14	3,017.
	Extraordinary items (net of tax expense) Net Profit for the period (11 - 12)	2,604.26	2,299.33	1,109.31	- 8,101.14	3,017.
10	Net Front for the period (11-12)	2,004.20	2,239.55	1,103.51	0,101.14	3,017.
14	Paid-up share capital	2,028.12	2,028.12	2,012.62	2,028.12	2,012.
15	(Face Value of Rs.10/- each) Reserves excluding Revaluation Reserve	32,403.15	30,629.37	25,036.69	32,403.15	25,036.
	Earnings per Share		·	·	·	•
	(a) Basic Earnings per share (Rs.)* (b) Diluted Earning per share (Rs) *	12.88 12.63	11.39 11.17	5.52 5.38	40.06 39.30	15.0 14.0
PARI						
PARI	Select Information for	the Quarter ar	nd year ended 31 M			
SI		3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013	Corresponding 3 Months ended 31 March, 2013 in the previous	Current year ended 31 March, 2014	ended
SI No.	Select Information for Particulars	3 Months ended 31	Preceding 3 Months ended 31 December,	Corresponding 3 Months ended 31 March, 2013	ended	ended
SI No.	Select Information for Particulars Public Shareholding	3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013	Corresponding 3 Months ended 31 March, 2013 in the previous year	ended 31 March, 2014	ended 31 March, 201
SI No.	Public Shareholding - No. of shares	3 Months ended 31	Preceding 3 Months ended 31 December,	Corresponding 3 Months ended 31 March, 2013 in the previous year	ended	ended 31 March, 201 11,182,09
SI No.	Select Information for Particulars Public Shareholding	3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013	Corresponding 3 Months ended 31 March, 2013 in the previous year	ended 31 March, 2014 10,370,988	ended 31 March, 201: 11,182,09
SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding	3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013	Corresponding 3 Months ended 31 March, 2013 in the previous year	ended 31 March, 2014 10,370,988	ended 31 March, 201: 11,182,09
SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered	3 Months ended 31 March, 2014 10,370,988 51.14%	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56%	ended 31 March, 2014 10,370,988 51.14%	ended 31 March, 201 11,182,09 55.56
SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding	3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56%	ended 31 March, 2014 10,370,988	ended 31 March, 201: 11,182,09 55.56
SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares	3 Months ended 31 March, 2014 10,370,988 51.14%	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56%	ended 31 March, 2014 10,370,988 51.14% 2,445,830	ended 31 March, 201: 11,182,09: 55.56' 840,000 9.36'
SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06%	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17%	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06%	ended 31 March, 2013 11,182,093 55.566 840,000 9.366 4.177
SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding Number of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06%	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336	ended 31 March, 201: 11,182,09' 55.56' 840,000' 9.36' 4.17'
SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06%	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61%	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06%	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
Si No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32%	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32%	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
2 2	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80% 3 Months ended 31	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61%	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32%	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
SI 1 2 2 SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Poper of shares Percentage of shares to total capital b) Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336 75,32% 36.80% 3 Months	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61%	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32%	ended 31 March, 201: 11,182,091 55.56' 840,000 9.36' 4.17' 8,104,05' 90.61'
SI 1 2 2 SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital Portentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 12.06% 7,464,336 75.32% 36.80% 3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61%	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32%	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
SI 1 2 2 SI No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80% 3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61%	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32%	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
SI 1 2 2 SI No.	Public Shareholding - No. of shares - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares to total capital b) Non-encumbered Number of shares to total capital Percentage of shares to total capital	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 12.06% 7,464,336 75.32% 36.80% 3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61%	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32%	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
A 1 2 2 Sil No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80% 3 Months ended 31 March, 2014	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61%	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32%	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
2 2 8 8 8 8 8 8 8 8 8	Public Shareholding Public Shareholding Power of shares Percentage of shareholding Promoters and promoter group Shareholding Promoters and promoter group Shareholding Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Number of shares Percentage of shares to total capital Number of shares Percentage of shares to total capital Particulars Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336 75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24,68% 12.06% 7,464,144 75.32% 36.80%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27%	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80%	ended 31 March, 201: 11,182,091 55.56' 840,000 9.36' 4.17' 8,104,05' 90.61'
SI No. 2 2 SI No. 3	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter	3 Months ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24,68% 12.06% 7,464,144 75.32% 36.80%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27%	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80%	ended 31 March, 201: 11,182,091 55.56' 840,000 9.36' 4.17' 8,104,05' 90.61'
Si No. 3	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter e financial results for the quarter and year ended 31st March, 2014 a approved by the Board of Directors at its meeting held on 24th Apie a auditors of the company have audited the above financial results.	3 Months ended 31 March, 2014 10,370,988 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL have been revierii, 2014.	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24,68% 12.06% 7,464,144 75.32% 36.80%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27%	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80%	ended 31 March, 201: 11,182,091 55.56' 840,000 9.36' 4.17' 8,104,05' 90.61'
SI No. 2 2 SI No. 3 I) The annual of the property of the prop	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, 2014 d approved by the Board of Directors at its meeting held on 24th Apie a auditors of the company have audited the above financial results. resuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by sign currency gains and losses on loans utilised for purchase of fixe	3 Months ended 31 March, 2014 10,370,988 51.14% 51.14% 24.45,830 24.68% 75.32% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL have been revieril, 2014. the Ministry of ad assets.	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% ommittee on 23rd Apr	ended 31 March, 2014 10,370,988 51,14% 2,445,830 24,68% 12,06% 7,464,336 75,32% 36,80% I, 2014	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
SI No. BB	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter et inancial results for the quarter and year ended 31st March, 2014 a approved by the Board of Directors at its meeting held on 24th App a auditors of the company have audited the above financial results. resuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by sign currency gains and losses on loans utilised for purchase of fixe Puring the quarter Gain of Rs. 429.94 laksh (Cani of Rs. 104.55 Laks), 104.55 Laksh (Cani of Rs. 104.55 Laks), 104.55 Laksh (Cani of Rs. 104.55 Laksh), 104.51 Laksh (Cani of Rs. 104.55 Laksh (Cani of Rs. 104.55 Laksh), 104.51 Laksh	3 Months ended 31 March, 2014 10,370,988 51.14% 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 120 20 20 NIIL 20 20 20 NIIL 2014. the Ministry of ed assets. ss for the Quarties of the Quarties of the Quarties of the Quarties of the Section 11, 2014.	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80%	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% ommittee on 23rd Apr	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336 75.32% 36.80% ii, 2014 to capitalise d to fixed assets.	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Cisposed of during the quarter and year ended 31st March, 2014 d) approved by the Board of Directors at its meeting held on 24th Ape a auditors of the company have audited the above financial results. Insulant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by sign currency gains and losses on loans utilised for purchase of fixuruing the quarter Capin of Rs.429.94 lakhs (Cain of Rs.104.55 Lakf vuring the quarter Capin of Rs.429.94 lakhs (Cain of Rs.104.55 Lakf vuring the quarter Capin of Rs.429.94 lakhs (Cain of Rs.104.55 Lakf vuring the quarter Capin of Rs.429.94 lakhs (Cain of Rs.104.55 Lakf vuring the quarter Capin of Rs.429.94 lakhs (Cain of Rs.104.55 Lakf vuring the financial year 2013-14 loss of Rs.1,562.85 (Previous yeaper clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the listing agreement, the Company has opted to year clause 41 of the list	3 Months ended 31 March, 2014 10,370,988 51.14% 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL the Ministry of the dassets. Is for the Quartur (2012-13 loss publish only core some part of the control of the cont	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80% wwed by the Audit Cr. Company Affairs, the ar ended 31 March in 6644.20 Lakhs) wisolidated financial in solidated financial in 1985.	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% ommittee on 23rd Apr e company has opted ecompany has opted est transferred to fixed est	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336 75.32% 36.80% ii, 2014 to capitalise d to fixed assets.	ended 31 March, 201 11,182,09 55.56 840,00 9.36 4.17 8,104,05 90.619
2 2 Sil No. 3 Sil No. 5 Si	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, 2014 a approved by the Board of Directors at its meeting held on 24th Ape a auditors of the company have audited the above financial results. resuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by sign currency gains and losses on loans utilised for purchase of fixe furing the quarter Gain of Rs. 429.94 laksh (Qain of Rs. 1,562.85 (Previous yea per clause 41 of the listing agreement, the Company has opted to ults are available for persual on the Company's website as well as	3 Months ended 31 March, 2014 10,370,988 51.14% 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 10.15 March, 2015 March, 2016 10.15 March, 2016 10.15 March, 2017 Marc	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80% wwed by the Audit Cr. Company Affairs, the ar ended 31 March in 6644.20 Lakhs) wisolidated financial in solidated financial in 1985.	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% ommittee on 23rd Apr e company has opted ecompany has opted est transferred to fixed est	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336 75.32% 36.80% ii, 2014 to capitalise d to fixed assets.	ended 31 March, 201 11,182,09 55.56 840,00 9.36 4.17 8,104,05 90.619
SI No. A 1 2 2 SI No. BB 11) The annual of fore fore fore fore fore fore fore f	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter et financial results for the quarter and year ended 31st March, 2014 d approved by the Board of Directors at its meeting held on 24th Ap e auditors of the company have audited the above financial results. rsuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by eign currency gains and losses on loans utilised for purchase of fixe buring the quarter Gain of Rs.429.94 lakhs (Gain of Rs.104.55 Lakf buring the quarter Gain of Rs.429.94 lakhs (Gain of Rs.104.55 Lakf buring the financial year 2013-14 loss of Rs.1,562.85 (Previous yea per clause 41 of the listing agreement, the Company has opted to jults are available for persual on the Company's website as well as w, granulesindia.com, www.bseindia.com and www.nse-india.com e Company operates only in the segment of Pharmaceuticals.	3 Months ended 31 March, 2014 10,370,988 51.14% 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 10.15 March, 2015 March, 2016 10.15 March, 2016 10.15 March, 2017 Marc	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80% wwed by the Audit Cr. Company Affairs, the ar ended 31 March in 6644.20 Lakhs) wisolidated financial in solidated financial in 1985.	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% ommittee on 23rd Apr e company has opted ecompany has opted est transferred to fixed est	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336 75.32% 36.80% ii, 2014 to capitalise d to fixed assets.	ended 31 March, 201 11,182,09 55.56 840,00 9.36 4.17 8,104,05 90.619
Sil No. 2 2 Sil No. 3 1) The annual fore control of the contr	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter ef inancial results for the quarter and year ended 31st March, 2014 d approved by the Board of Directors at its meeting held on 24th Ap e auditors of the company have audited the above financial results. resuant to the Notification No.G.S.R.913(F), dt.29.12.2011 issued by sign currency gains and losses on loans utilised for pruchase of fixe furing the quarter Gain of Rs. 429.94 lakhs (Gain of Rs. 104.55 Lakh) uring the quarter Gain of Rs. 429.94 lakhs (Gain of Rs. 104.55 Lakh) uring the quarter Gain of Rs. 429.94 lakhs (Gain of Rs. 104.55 Lakh) uring the quarter Gain of Rs. 429.94 lakhs (Gain of Rs. 104.55 Lakh) uring the quarter Gain of Rs. 429.94 lakhs (Gain of Rs. 104.55 Lakh) uring the quarter Gain of Rs. 429.94 lakhs (Gain of Rs. 104.55 Lakh) uring the grouped wherever necessary.	3 Months ended 31 March, 2014 10,370,988 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL have been revieril, 2014. the Ministry of ad assets. so for the Quartur 2012-13 loss publish only cor on the stock ex	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80% weed by the Audit Co	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% ommittee on 23rd Apr e company has opted ecompany has opted est transferred to fixed est	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24,68% 12.06% 7,464,336 75.32% 36.80% ii, 2014 to capitalise d to fixed assets.	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
2 2 2 Silvo. A 1 1 2 2 2 Silvo. B 3 Pun forest Pun service Silvo. C 1 Pun service Silvo. C 2 Silvo. C 3 Silvo. C 4 Silvo. C 5 Silvo. C 6 Silvo. C 7 Silvo. C 8 Silvo. C 9 Silvo. C 1 Silvo. C 1 Silvo. C 1 Silvo. C 1 Silvo. C 2 Silvo. C 2 Silvo. C 3 Silvo. C 4 Silvo. C 5 Silvo. C 6 Silvo. C 7 Silvo. C 7 Silvo. C 8 Silvo. C 9 Silvo	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter et financial results for the quarter and year ended 31st March, 2014 d approved by the Board of Directors at its meeting held on 24th Ap e auditors of the company have audited the above financial results. rsuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by eign currency gains and losses on loans utilised for purchase of fixe buring the quarter Gain of Rs.429.94 lakhs (Gain of Rs.104.55 Lakf buring the quarter Gain of Rs.429.94 lakhs (Gain of Rs.104.55 Lakf buring the financial year 2013-14 loss of Rs.1,562.85 (Previous yea per clause 41 of the listing agreement, the Company has opted to jults are available for persual on the Company's website as well as w, granulesindia.com, www.bseindia.com and www.nse-india.com e Company operates only in the segment of Pharmaceuticals.	3 Months ended 31 March, 2014 10,370,988 51.14% 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL have been revieril, 2014. the Ministry of ded assets. so for the Quartur 2012-13 loss publish only coron the stock exerges of Rs.10/- or the stock exerges o	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80% weed by the Audit Company Affairs, the er ended 31 March: of 644.20 Lakhs) wisolidated financial richanges' websites.	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% ommittee on 23rd Apr e company has opted 2013) was transferred to fixee sesults. The stand-aid as stated below:	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80% il, 2014 to capitalise d to fixed assets. assets. ne financial	ended 31 March, 201: 11,182,09' 55.56' 840,00 9.36' 4.17' 8,104,05' 90.61'
2 2 2 Sil No. 3 3 Sil No. 5 Sil No.	Public Shareholding - No. of shares - Percentage of shareholding Promoters and promoter group Shareholding Promoters and promoter group Shareholding a) Pledged/Encumbered Number of shares Percentage of shares to promoter group Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital b) Non-encumbered Number of shares Percentage of shares to total capital Percentage of shares to promoter group Percentage of shares to promoter group Percentage of shares to total capital Particulars INVESTOR COMPLAINTS Pending at the beginning of the Quarter Received during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter en financial results for the quarter and year ended 31st March, 2014. If approved by the Board of Directors at its meeting held on 24th Apie auditors of the company have audited the above financial results. Insulant to the Notification No.G.S.R.9.13[E], dt.29.12.2011 issued by sign currency gains and losses on loans utilised for purchase of fixe furning the quarter Gain of Rs.429.94 lakhs (Gain of Rs.104.55 Laki Yuring the financial year 2013-14 loss of Rs.1,562.85 (Previous yea per clause 41 of the listing agreement, the Company has opted to jults are available for persual on the Company's website as well as we granulesindia.com, www.bseindia.com and www.nse-india.com a Company, during the current year has allotted 1,55,000 equity she	3 Months ended 31 March, 2014 10,370,988 51.14% 51.14% 24.45,830 24.68% 12.06% 36.80% 3 Months ended 31 March, 2014 NIL 20 20 NIL have been revieril, 2014. the Ministry of ded assets. so for the Quartur 2012-13 loss publish only coron the stock exerges of Rs.10/- or the stock exerges o	Preceding 3 Months ended 31 December, 2013 10,371,180 51.14% 2,445,830 24.68% 12.06% 7,464,144 75.32% 36.80% weed by the Audit Company Affairs, the er ended 31 March: of 644.20 Lakhs) wisolidated financial richanges' websites.	Corresponding 3 Months ended 31 March, 2013 in the previous year 11,182,097 55.56% 840,000 9.36% 4.17% 8,104,057 90.61% 40.27% committee on 23rd Apr e company has opted 2013) was transferred to fixed results. The stand-alcas stated below:	ended 31 March, 2014 10,370,988 51.14% 2,445,830 24.68% 12.06% 7,464,336 75.32% 36.80% ii, 2014 to capitalise d to fixed assets. assets. assets. ane financial	Previous year ended 31 March, 2013 11,182,097 55.563 840,000 9.365 4.175 90.61% 40.275



	Standalone Statement of Asset	is allu Liavililies	(Dointalde
		A4	(Rs in Lakhs)
		As at	As at
		current year	previous year
	Particulars	end	end
_	EQUITY AND LIABILITIES	31 March, 2014	31 March, 2013
A _	EQUITY AND LIABILITIES		
1	Shareholders' Funds	0.000.40	0.040.00
	(a) Share Capital	2,028.12	2,012.62
	(b) Reserves & Surplus	32,403.15	25,036.69
	Sub-total - Shareholders' funds	34,431.27	27,049.30
2	Share Application Money Pending Allotment	25.48	31.50
3		22 200 49	14.070.0
	(a) Long-term borrowings	22,209.18	14,072.3
	(b) Deferred tax liabilities (Net)	3,580.81	2,509.8
	(c) Long-term provisions	369.90	212.3
_	Sub-total - Non-current liabilities	26,159.88	16,794.6
4	Controller managements	7 740 00	7.074.4
	(a) Short-term borrowings	7,748.62	7,671.4
	(b) Trade payables	12,624.80	8,384.7
	(c) Other current liabilities	3,760.49	1,292.6
	(d) Short-term provisions	830.48	470.9
	Sub-total - Current liabilities	•	17,819.8
3	TOTAL - EQUITY AND LIABILITIES ASSETS	85,581.03	61,695.2
1			
	(a) Fixed Assets		
	(i) Tangible assets	32,642.86	23,240.0
	(ii) Intangible assets	924.43	1,243.3
	(iii) Capital work-in-progress	3,914.21	9,160.2
	(III) Capital Work-III-progress	37,481.50	33,643.7
	(b) Non-current investments	14,544.61	4,129.6
	(c) Long-term loans and advances	314.66	1,252.7
	(c) Long-term loans and advances		357.6
	(d) Other non-current assets		
	(d) Other non-current assets	255.58 52 596 3 4	
2	Sub-total - Non-current assets	52,596.34	
2	Sub-total - Non-current assets Current assets		39,383.7
2	Sub-total - Non-current assets Current assets (a) Current Investments	52,596.34	39,383.7 945.9
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories	52,596.34 - 12,028.73	39,383.7 945.9 10,849.0
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories (c) Trade receivables	52,596.34 - 12,028.73 12,181.97	39,383.7 945.9 10,849.0 6,809.6
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories (c) Trade receivables (d) Cash and cash equivalents	52,596.34 - 12,028.73 12,181.97 2,192.58	945.9 10,849.0 6,809.6 615.9
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories (c) Trade receivables (d) Cash and cash equivalents (e) Short-term loans and advances	52,596.34 - 12,028.73 12,181.97 2,192.58 314.34	39,383.7 945.9 10,849.0 6,809.6 615.9 564.7
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories (c) Trade receivables (d) Cash and cash equivalents (e) Short-term loans and advances (f) Other current assets	52,596.34 - 12,028.73 12,181.97 2,192.58 314.34 6,267.06	945.9 10,849.0 6,809.6 615.9 564.7 2,526.1
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories (c) Trade receivables (d) Cash and cash equivalents (e) Short-term loans and advances (f) Other current assets Sub-total - Current assets	52,596.34 - 12,028.73 12,181.97 2,192.58 314.34 6,267.06 32,984.68	39,383.7 945.9 10,849.0 6,809.6 615.9 564.7 2,526.1 22,311.5
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories (c) Trade receivables (d) Cash and cash equivalents (e) Short-term loans and advances (f) Other current assets	52,596.34 - 12,028.73 12,181.97 2,192.58 314.34 6,267.06 32,984.68 85,581.03	39,383.7 945.9 10,849.0 6,809.6 615.9 564.7 2,526.1 22,311.5 61,695.2
2	Sub-total - Non-current assets Current assets (a) Current Investments (b) Inventories (c) Trade receivables (d) Cash and cash equivalents (e) Short-term loans and advances (f) Other current assets Sub-total - Current assets	52,596.34 - 12,028.73 12,181.97 2,192.58 314.34 6,267.06 32,984.68	39,383.7 945.9 10,849.0 6,809.6 615.9 564.7 2,526.1 22,311.5 61,695.2